Pitavastatin

@article{Mukhtar2005Pitavastatin,
  title={Pitavastatin},
  author={Rasha Mukhtar and J. Reid and John P. D. Reckless},
  journal={International Journal of Clinical Practice},
  year={2005},
  volume={59}
}
The growing number of trials that have highlighted the benefit of intensive lowering of total‐ and low density lipoprotein (LDL)‐cholesterol levels especially with statins has created a need for more efficacious agents. Pitavastatin is a new synthetic 3‐hydroxy‐3‐methyl glutaryl coenzyme A reductase inhibitor, which was developed, and has been available in Japan since July 2003. 
An evaluation of pitavastatin for the treatment of hypercholesterolemia
TLDR
Pitavastatin produces dose-dependent reductions in LDL-C at lower doses than other statins, and it was found to be less likely to cause new onset diabetes and the highest dose may be preferred in high-risk patients.
New drugs for the treatment of hypercholesterolaemia
TLDR
Two new and more potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), also called superstatins (rosuvastatin and pitavastatin), are being studied for their ability to improve lipid profiles.
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
TLDR
The pharmacokinetics of the available and emerging treatments for hypercholesterolemia are reviewed and focus on recently approved drugs and those at a late stage of development.
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins
TLDR
Recommendations on in vitro evaluation of statin interaction potential, discussing how reduced transporter activity impacts statin management during drug development, and proposing ideas on how to evaluate the impact of DDI on statin efficacy during clinical trials are provided.
Efficacy of Pitavastatin , a New HMG-CoA Reductase Inhibitor , on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes
TLDR
The first case of type III allergy to the new longacting insulin analog detemir is reported, affecting a 31-yearold man with type 1 diabetes who had been treated by glargine once daily and aspart before each meal for 2 years.
Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis.
TLDR
Detailed knowledge of characteristics and differences of each kind of available statin could help the physician in the correct choice, based on patient's clinical profile, of this essential tool with a demonstrated high cost-effectiveness both in primary than in the secondary prevention of cardiovascular disease.
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study
TLDR
While both statins similarly reduced plasma lipids, only pitavastatin increased plasma VEGF level and circulating EPCs in high-risk patients, which is probably related to the differential pleiotropic effects of different statins.
Pitavastatin in cardiometabolic disease: therapeutic profile
  • L. Masana
  • Biology, Medicine
    Cardiovascular Diabetology
  • 2013
Statins effectively lower low-density lipoprotein-cholesterol (LDL-C) and reduce cardiovascular risk in people with dyslipidemia and cardiometabolic diseases such as Metabolic syndrome (MetS) or type
Effect of Pitavastatin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Nondiabetic Mild Chronic Kidney Disease
TLDR
The present data suggest that pitavastatin ameliorates tubulointerstitial damage in CKD patients independent of the lipid-lowering effect.
Pitavastatin for lowering lipids.
TLDR
Pitavastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a linear fashion and when compared to other statins for its effect to reduce LDL cholesterol, pitavASTatin is about 6-fold more potent than atorvastatin, 1.7-foldMore potent than rosuvastasin, 77-foldmore potent than fluvastarin and 3.3-fold less potent than cerivastatin.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 114 REFERENCES
Novel Statins: Pharmacological and Clinical Results
TLDR
As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased cholesterol lowering potency may ensure the achievement of target cholesterol levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.
Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
TLDR
Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at doses of 1mg/day or more, and significant dose-dependence of the effect of this drug was observed within the dose range from 1 mg/ day to 4 mg/day.
Novel approaches to lipid lowering: what is on the horizon?
  • W. Brown
  • Biology, Chemistry
    The American journal of cardiology
  • 2001
Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
TLDR
Pitavastatin is a novel, fully synthetic statin, which has a potent cholesterol-lowering action and could provide a new and potentially better therapeutic choice for lipid-modifying therapy than do the currently available statins.
NK-104: a novel synthetic HMG-CoA reductase inhibitor
TLDR
Results supported the ‘lower is better’ hypothesis in the relationship between LDL-cholesterol levels and CAD and suggested NK-104 can provide a new and potentially superior therapeutic agent when compared with currently available other statins.
Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin
TLDR
This article summarizes the pharmacological data of five novel statins and points out potential mechanisms leading to increased toxicity since the prevalence of adverse events can be explained at least in part by their pharmacokinetic differences.
Statins: the new aspirin?
TLDR
The targets and mechanisms of action of statins are described in detail, showing that pleiotropic effects extend far beyond cholesterol reduction and involve non-lipid-related mechanisms that modify endothelial functions, immunoinflammatory responses, smooth muscle cell activation, proliferation and migration, atherosclerotic plaque stability, and thrombus formation.
Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor.
  • W. Isley
  • Biology, Chemistry
    Drugs of today
  • 2001
TLDR
Early studies suggest that Pitavastatin calcium may be quite useful for treating common dyslipidemias and may produce marked reductions in triglyceride-rich particles, which are proven to have positive effects on cardiovascular risk.
...
1
2
3
4
5
...